Table 5 Process indicators among women with severe maternal morbidity and mortality
1. Prevention of PPH | n (%) |
|---|---|
Target population: women who delivered in hospital | 201 (100%) |
Oxytocin use for AMTSL | 96 (48%) |
Other uterotonic use for AMTSL | 2 (1%) |
All uterotonic use for AMTSL | 96 (48%) |
2. Treatment of PPH | |
Target population: women with PPH | 66 (100%) |
Delivery in hospital | 41 (62%) |
Delivery out hospital | 25 (38%) |
Oxytocin use (routine) | 28 (42%) |
Other uterotonic use (routine) | - |
All uterotonic use (routine) | 28 (42%) |
Oxytocin use (treatment) | 38 (58%) |
Other uterotonic use (treatment) | 10 (15%) |
All uterotonic use (treatment) | 39 (59%) |
IV-infusion | 54 (82%) |
Blood products | 61 (92%) |
Hysterectomy | 4 (6%) |
CFR | 9% |
3. Treatment of eclampsia | |
Target population: women with eclampsia | 15 (100%) |
Magnesium sulphate use | 13 (87%) |
Other anticonvulsant use | 10 (67%) |
Any anticonvulsant use | 14 (93%) |
CFR | 7% |
4. Prevention of caesarean section related infection | |
Target population: women with caesarean section | 74 (100%) |
Prophylactic antibiotics | 49 (66%) |
5. Treatment of sepsis | |
Target population: women with sepsis | 30 (100%) |
Parenteral therapeutic antibiotics | 28 (93%) |
CFR | 27% |
6. Uterine rupture | |
Target population: women with uterine rupture | 21 (100%) |
Occurred in hospital | 13 (62%) |
Occurred out hospital | 8 (38%) |
Laparotomy | 21 (100%) |
CFR | 5% |